News

Filter


RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023

View News

RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)

View News

RayzeBio Appoints Industry Veteran Rich Heyman, Ph.D. as Chairman of Board of Directors

View News

RayzeBio to Present at Upcoming Investor Conferences in November 2022

View News

RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications

View News

RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer

View News

PeptiDream and RayzeBio Announce Expansion of Strategic Partnership for the Discovery of Novel Peptide Radiopharmaceutical Therapeutics

View News

RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

View News

RayzeBio Expands Leadership Team with Arvind Kush, as Chief Financial Officer; and Aubrey Haddach, J.D., as General Counsel

View News

RayzeBio to Present at J.P. Morgan Healthcare Virtual Conference on Tuesday, January 11, 2022

View News

RayzeBio Appoints Mary Tagliaferri, M.D. to its Board of Directors and Expands Leadership Team with Rozalyn Littler as VP of Regulatory and Quality

View News

RayzeBio Expands Leadership Team with Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation

View News

48Hour Discovery and RayzeBio Announce strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals

View News

Nimble Therapeutics and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals

View News

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

View News

RayzeBio Appoints Yi Larson to Its Board of Directors and Expands Team with Key Leadership Hires

View News

RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer

View News

RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics

View News

PeptiDream Announces Strategic Partnership with RayzeBio for the Discovery and Development of Peptide-Radiotherapeutics

View News